Advertisement
Organisation › Details
Gain Therapeutics (Group)
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. *
Start | 2017-12-31 established (s-off) | |
Predecessor | Minoryx Therapeutics S.L. | |
Industry | SEE-Tx platform (Site-directed Enzyme Enhancement Therapy platform | |
Person | Leoni, Lorenzo (TiVenture Fund 201802 Managing Director + Gain Therapeutics 201802– interim CEO before Telormedix) | |
Person 2 | Barril, Xavier (Gain Therapeutics 201802 CSO before Minoryx Therapeutics + Vernalis) | |
Region | Lugano TI | |
Country | Switzerland | |
Street | 6 Via Francesco Soave | |
City | 6900 Lugano TI | |
Tel | +41-91-921-1131 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2021-12-31) |
Currency | USD | |
Annual sales | 164,994 (revenues, total, consolidated (2021) 2021-12-31) | |
Profit | -13,890,606 (2021-12-31) | |
Cash | 36,880,673 (2031-12-31) | |
* Document for »About Section«: Gain Therapeutics, Inc.. (9/10/20). "Press Release: Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program". Bethesda, MD. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Gain Therapeutics (Group)
- [1] Gain Therapeutics, Inc.. (9/10/20). "Press Release: Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program". Bethesda, MD....
- [2] Gain Therapeutics, Inc.. (7/21/20). "Press Release: Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing". Bethesda, MD....
- [3] Gain Therapeutics SA. (9/12/19). "Press Release: Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors". Lugano....
- [4] Gain Therapeutics SA. (7/23/19). "Press Release: Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2". Lugano, Bellinzona & Gardanne....
- [5] Gain Therapeutics SA. (2/26/19). "Press Release: Gain Therapeutics SA Announces Award of Grant Support from Leading Parkinson’s Research Foundations to Advance Its Proprietary Non Competitive Molecular Chaperones for Parkinson’s Disease". Lugano & Bar...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top